BAT market seen topping $106B by 2030, led by North America

A new report from The Business Research Company projects the global BAT market will reach more than $106 billion by 2030, with North America and the U.S. leading growth. The forecast points to infant botulism as the largest segment and says preparedness spending, foodborne cases and earlier treatment awareness are key drivers.

Why it matters: - BAT, or botulism antitoxin heptavalent, is forecast to become a much larger emergency-response and anti-infective market through 2030. - The projected scale suggests rising demand tied to bioterror preparedness, stockpiling and faster botulism treatment. - The report also places BAT at nearly 4% of the wider pharmaceuticals market by 2030, showing the category's outsized value within a niche therapy area.

What happened: - The Business Research Company released a 2026 market report projecting the BAT market will surpass $106 billion in 2030. - The report estimates the BAT market will grow at a 16% CAGR leading up to 2030. - North America is projected to be the largest region in 2030, at $75 billion. - The U.S. is projected to be the largest country in 2030, at $71 billion. - The infant botulism segment is projected to be the largest indication segment in 2030, with 55% of the market, or $58 billion. - The report segments the market by indication, distribution channel and end user. - Distribution channels include hospitals, pharmacies and online pharmacies. - End users include adult and pediatric patients. - The report is available as a free sample and as the full market report.

The details: - North America is expected to grow from $42 billion in 2025 to $75 billion in 2030, a 12% CAGR. - The report links that regional growth to bioterror preparedness, public health stockpiling, early diagnosis awareness, healthcare infrastructure and rare disease investment. - The U.S. market is expected to rise from $41 billion in 2025 to $71 billion in 2030, also at a 12% CAGR. - The report ties U.S. growth to foodborne illness surveillance, healthcare spending, public health coordination, clinical awareness and biodefense investment. - The infant botulism market is expected to grow on better symptom recognition, stronger neonatal and pediatric critical care, faster intervention and improved treatment access. - The report says the infant botulism market will be supported by specialized healthcare distribution networks. - The most significant growth opportunities are expected in foodborne botulism, wound botulism and infant botulism. - Those three segments are projected to add more than $56 billion in market value by 2030. - The infant botulism market is projected to grow by $31 billion from 2025 to 2030. - The foodborne botulism market is projected to grow by $19 billion over the same period. - The wound botulism market is projected to grow by $6 billion over the same period.

Between the lines: - The report frames BAT demand as a function of emergency readiness, not routine chronic care. - The strongest growth assumptions come from public-sector preparedness and clinical speed, which suggests procurement and response infrastructure matter as much as patient volume. - The report's projections also show how rare but severe toxin-related conditions can command large market values when governments and health systems stockpile countermeasures. - The Business Research Company says its latest 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and future trend analysis.

What's next: - BAT growth will likely track how governments expand stockpiles and how quickly health systems identify and treat botulism cases. - The report expects continued momentum in the foodborne, wound and infant botulism segments through 2030. - The Business Research Company says it will continue publishing updated market reports across industries and geographies.

The bottom line: - BAT is still a specialized market, but the report expects it to become a major global category by 2030 as preparedness and early treatment priorities accelerate demand.